Irbesartan in patients with atrial fibrillation

S Yusuf; JS Healey; J Pogue; S Chrolavicius; M Flather; RG Hart; SH Hohnloser; CD Joyner; MA Pfeffer; SJ Connolly

doi:10.1056/NEJMoa1008816

Irbesartan in patients with atrial fibrillation

S Yusuf, JS Healey, J Pogue, S Chrolavicius, M Flather, RG Hart, SH Hohnloser, CD Joyner, MA Pfeffer, SJ Connolly

Research output: Contribution to journal › Article

173 Citations (Scopus)

Abstract

Irbesartan did not reduce cardiovascular events in patients with atrial fibrillation. (Funded by Bristol-Myers Squibb and Sanofi-Aventis; ClinicalTrials.gov number, NCT00249795.).

Original language	English
Pages (from-to)	928-938
Number of pages	11
Journal	New England Journal of Medicine
Volume	364
Issue number	10
DOIs	https://doi.org/10.1056/NEJMoa1008816
Publication status	Published - 2011

Access to Document

10.1056/NEJMoa1008816

Cite this

@article{94e859ad413b44e7a59982dbe466c535,

title = "Irbesartan in patients with atrial fibrillation",

abstract = "Irbesartan did not reduce cardiovascular events in patients with atrial fibrillation. (Funded by Bristol-Myers Squibb and Sanofi-Aventis; ClinicalTrials.gov number, NCT00249795.).",

author = "S Yusuf and JS Healey and J Pogue and S Chrolavicius and M Flather and RG Hart and SH Hohnloser and CD Joyner and MA Pfeffer and SJ Connolly",

year = "2011",

doi = "10.1056/NEJMoa1008816",

language = "English",

volume = "364",

pages = "928--938",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "10",

}

TY - JOUR

T1 - Irbesartan in patients with atrial fibrillation

AU - Yusuf, S

AU - Healey, JS

AU - Pogue, J

AU - Chrolavicius, S

AU - Flather, M

AU - Hart, RG

AU - Hohnloser, SH

AU - Joyner, CD

AU - Pfeffer, MA

AU - Connolly, SJ

PY - 2011

Y1 - 2011

N2 - Irbesartan did not reduce cardiovascular events in patients with atrial fibrillation. (Funded by Bristol-Myers Squibb and Sanofi-Aventis; ClinicalTrials.gov number, NCT00249795.).

AB - Irbesartan did not reduce cardiovascular events in patients with atrial fibrillation. (Funded by Bristol-Myers Squibb and Sanofi-Aventis; ClinicalTrials.gov number, NCT00249795.).

U2 - 10.1056/NEJMoa1008816

DO - 10.1056/NEJMoa1008816

M3 - Article

VL - 364

SP - 928

EP - 938

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -